中国核电股价的疲弱不仅让投资者出现了损失，也让自家的回购账户出现了浮亏。2月2日，中国核电公告称，截至2026年1月31日，公司累计回购股份数量 为4490.17万股，占公司目前总股本的比例为0.22%，购买的最高价为9.65元/股，购买的最低价为8.40元/股，已支付的总金额为4.05亿元（不含佣金等交易 费用），以此计算，其回购均价为9.02元/股。而2月3日的收盘价8.56元已然在公司的回购均价之下。 每经记者｜闫峰峰 每经编辑｜吴永久 近一年多来，与A股走牛形成鲜明对比的是中国核电的股价疲弱走势，自2024年"9·24行情"以来（截至2026年2月3日），中国核电股价落后上证指数61.71个 百分点！而中国核电的股价也跌破了公司的回购均价，并再次逼近全国社会保障基金理事会（以下简称社保基金会）的定增认购价。 中国核电在牛市中走出独立下跌行情，令投资者困惑不已。那么，公司基本面上到底发生了什么？公司股价还会再次在社保基金会成本价获得支撑吗？ 《每日经济新闻》记者发现，虽然中国核电业绩承压股价疲弱，但公司布局的"战略新兴产业"业务表现出不少亮点。 近一年多来，多个A股重要指数走出牛市行情。如自2024年" ...

首套国产重离子治癌设备打破国外垄断；万米海洋钻机、医用同位素等产品和技术达到世界一流水平； 认定培育了25家概念验证中心和中试基地，每万人口发明专利拥有量达到32件，累计实现技术合同成交 额370.75亿元……"十四五"期间，甘肃省兰州市科技创新成果不断涌现且高效转化，综合科技进步水平 指数达到82.61%，跃居全球科研城市百强榜第48位。 兰州拥有丰富的科创资源，"十四五"时期完成重组的12家全国重点实验室，新组建的14个院士专家人才 工作站和43名两院院士，以及兰州大学、中国科学院兰州分院、驻甘央企等主力科研力量，是我们过去 5年取得亮眼成绩的基础支撑。"十五五"时期，我们将继续创新体制机制，促进各类要素资源高效配 置，构筑全域创新格局，全力建设国家重要的区域性科技创新高地。 （文章来源：经济日报） 具体来说，我们将发挥好兰州新区、高新区、经开区的政策叠加优势，探索实施科产融合促成果转化激 励计划、科技研发综合型服务企业培育计划以及科创平台建设"全国合伙人"计划等措施，全力建设包括 兰州智汇科技创新园在内的"黄河百里科创大走廊"20个科创平台，打造引领新质生产力发展的特色核心 孵化区。 同时，我们将坚持" ...

Group 1 - The event "2025 Foreign Investment Institutions Chengdu Tour" was held on December 9, featuring over 40 foreign investment institutions and local enterprises, with 12 high-tech companies presenting their financing needs totaling nearly 1 billion yuan [1][21] - The participating companies span various sectors including biomedicine, satellite communication, artificial intelligence, advanced manufacturing, and new energy, representing the growth status of Chengdu's tech enterprises [3][19] - Chengdu Guoxing Aerospace Technology Co., Ltd. focuses on building AI-enabled space computing infrastructure and offers global services in space computing and AI technology [3] - Chengdu Olin Biotech Co., Ltd. is a national high-tech enterprise specializing in the research, development, production, and commercialization of human vaccines, successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in June 2021 [5] - Chengdu Jin Xin Kang Yang Industry Group Co., Ltd. has been a pioneer in integrating medical and elderly care services in China, focusing on comprehensive urban elderly care solutions [7] Group 2 - Chengdu Boen Medical Robotics Co., Ltd. has developed AI-controlled surgical robots that automate laparoscopic surgeries, achieving multiple industry firsts [8] - Sichuan Zhishan Weixin Biotechnology Co., Ltd. specializes in gene therapy for genetic diseases and aging, being the first in China to have innovative gene drugs for hemophilia and Fabry disease approved for clinical trials, seeking 250-300 million yuan in financing [10] - Chengdu Weijin Bai Ao Biopharmaceutical Technology Co., Ltd. has a unique drug VG712 that can reset the immune system for cancer patients, with a financing demand of 70 million yuan [12] - Chengdu Lu Jia Isotope Technology Co., Ltd. focuses on the innovation and localization of medical isotopes, with a financing requirement of 20 million yuan [14] - Chengdu Wabo Technology Co., Ltd. is developing brain-computer interface technology and aims to target the consumer market, seeking 12 million yuan for 10% equity [16] Group 3 - Chengdu Ximeng Zhijian Technology Co., Ltd. provides one-stop scientific computing and intelligent simulation solutions, enhancing innovation efficiency through AI-driven research [17] - Sichuan Jinding Group Co., Ltd. focuses on the integration of AI and green energy technologies, with a financing need of 50 million yuan for its logistics and mining sectors [19] - The event facilitated in-depth communication between foreign investment institutions and local companies, with several firms expressing interest in establishing connections for future collaboration [21][23] - Chengdu Weijin Bai Ao Biopharmaceutical Technology Co., Ltd. secured a million-level equity investment intention after the roadshow, highlighting the potential of its core project VG712 [25]

Core Insights - The company, China General Nuclear Power Technology (CGN), announced on November 3 that its medical isotope production is a fundamental raw material for the development of nuclear pharmaceuticals, positioning it in the upstream segment of the nuclear medicine industry [2] Group 1 - The core production equipment for the isotope business, including accelerator main devices and process hot rooms, has been delivered and is currently undergoing installation and debugging [2] - The company plans to commence production in 2026 [2]

Group 1: Proton Medical Equipment and Isotope Production - Proton medical equipment from the Huaxi project has completed factory production, but installation is pending site readiness, with no acceptance expected this year [2] - The company is focusing on domestic isotope production, particularly the germanium-gallium generator, which is in a critical phase from technical breakthroughs to large-scale supply [2][3] - The company plans to produce isotopes such as germanium-68 and iodine-123, with stable delivery based on customer orders once production starts [3] Group 2: Research and Development Investments - The company has developed a high-power industrial irradiation electron accelerator for disinfection, which offers higher power and efficiency compared to traditional models [4] - New materials like XETFE, suitable for aerospace applications, have been developed, achieving small-scale sales and targeting both domestic and international markets [7] - The company is also advancing in the production of copper-64 and zirconium-89 isotopes, with plans for future industrialization based on market demand [4] Group 3: Financial Performance and Strategic Measures - The company has faced two consecutive years of losses but is implementing measures to reduce costs and increase revenue, including strategic collaborations with major clients [8] - Plans for product transformation and innovation enhancement are underway to align with market demands [8] - The company aims to improve operational efficiency through comprehensive reforms [8]

Core Viewpoint - The article provides an overview of the latest trends in investment and financing activities in the domestic market, highlighting key sectors and significant financing events. Group 1: Investment Overview - This week, there were 109 disclosed financing events in the domestic primary market, an increase of 12 compared to the previous week. Among these, 36 events disclosed financing amounts, totaling 4.786 billion RMB, with an average financing amount of 133 million RMB [7]. - The most active sectors in terms of financing events were intelligent manufacturing, artificial intelligence, and healthcare, with 21, 16, and 13 events respectively [9]. Group 2: Sector Highlights - In terms of disclosed financing amounts, artificial intelligence led with a total financing scale of approximately 1.055 billion RMB. Notably, the bionic robot developer "Wubai Intelligent" secured nearly 500 million RMB in Series A financing [9][10]. - The healthcare sector followed with a disclosed financing total of 670 million RMB, where the medical isotope developer "Nuclear Element Innovation" received 430 million RMB in Series A financing [10]. Group 3: Regional Distribution - The disclosed financing events were primarily concentrated in Jiangsu, Zhejiang, and Guangdong, with Jiangsu reporting 24 events, Zhejiang 19 events, and Guangdong 18 events [14][17]. Group 4: Stage Distribution - The stage distribution of the disclosed financing events showed that 81 were early-stage, 24 were growth-stage, and 4 were late-stage [17]. Group 5: Major Financing Events - The article mentions significant financing events, including the acquisition of 70% of the semiconductor packaging materials manufacturer "Huawei Electronics" by Huahai Chengke for 1.12 billion RMB [35][37]. Group 6: Active Investment Institutions - The most active investment institutions this week included CRRC Capital with 4 investment events, Shenzhen Capital Group with 3, and Legend Capital with 2 [24]. Group 7: IPO Highlights - A total of 8 companies were monitored for IPOs this week, with the highest market capitalization being "Sany Heavy Industry" at 212.898 billion HKD. All listed companies had previously received VC/PE or CVC investments [28][29].

Core Viewpoint - China General Nuclear Power Technology Co., Ltd. (CGN Tech) is a leading enterprise in non-power nuclear technology, focusing on accelerator manufacturing and irradiation processing services, with a strategic emphasis on its core business [1][5]. Financial Performance - For Q3 2025, CGN Tech reported revenue of 4.065 billion yuan, ranking 8th in the industry, significantly above the industry average of 1.994 billion yuan but far below the top competitor, Sinochem International, at 35.716 billion yuan [2]. - The company's net profit for the same period was -109 million yuan, placing it 74th in the industry, which is considerably lower than the industry average net profit of 74.438 million yuan [2]. - The main business composition includes new materials at 2.136 billion yuan (82.38%), with other segments contributing 220 million yuan (8.49%) and electronic accelerators and irradiation processing at 218 million yuan (8.40%) [2]. Financial Ratios - As of Q3 2025, CGN Tech's debt-to-asset ratio was 44.49%, down from 47.95% year-on-year, but still above the industry average of 34.74% [3]. - The gross profit margin for the same period was 13.47%, an increase from 12.50% year-on-year, yet still below the industry average of 19.93% [3]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 17.23% to 48,400, while the average number of circulating A-shares held per shareholder increased by 28.65% to 17,400 [5]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with notable changes in their holdings [5]. Business Highlights - CGN Tech is recognized as the only manufacturing champion in the domestic electronic accelerator sector, with a production capacity of 90 units per year and a 30% increase in accelerator sales expected in 2024 [6]. - The company is expanding its nuclear medicine sector with the proton therapy equipment and isotope production, with production expected to commence soon [5][6]. - Revenue projections for 2025 to 2027 are 6.760 billion yuan, 7.708 billion yuan, and 8.206 billion yuan, respectively, with net profits expected to rise from 55 million yuan in 2025 to 221 million yuan in 2027 [5][6].

Core Insights - The 2025 International Conference on Nuclear Technology Applications opened in Chengdu, Sichuan, with representatives from 16 countries and regions discussing the role of nuclear technology in sustainable global development and sharing industry opportunities [1][3] Group 1: Industry Development - Sichuan province is focusing on strategic opportunities to enhance its nuclear medical industry, having established over 20 high-level innovation platforms and achieved breakthroughs in the independent research and preparation of 15 types of medical isotopes [3][4] - The city of Leshan, known as the "cradle of nuclear power engineering," has developed China's first dedicated medical isotope reactor, creating a complete industrial chain of "reactor, equipment, isotopes, and pharmaceuticals" [3][4] Group 2: Policy Framework - The current development strategy for the nuclear technology application industry is centered around a "2+1" policy framework, which includes the "Medium and Long-term Development Plan for Medical Isotopes (2021-2035)," the "Three-Year Action Plan for High-Quality Development of Nuclear Technology Application Industry (2024-2026)," and the "Guiding Opinions on the Development of Nuclear Technology Application Industry (2026-2035)" [4][6] - The "Medium and Long-term Development Plan for Medical Isotopes" focuses on establishing a stable supply system through 13 tasks related to technology research and supply capacity enhancement [4][6] Group 3: Collaborative Efforts - The conference included a signing ceremony for strategic cooperation agreements between local governments and various research institutions, focusing on projects such as the production of medical isotopes using a 75MeV high-current cyclotron and the establishment of an international nuclear technology application innovation industrial base [6][8] - The event, hosted by the China Nuclear Energy Industry Association, will last for three days and feature thematic reports, academic meetings, and technical visits to explore industry hotspots and future development trends [8]

Core Insights - The Sichuan government is prioritizing the development of the nuclear medicine industry, aiming to establish a world-class nuclear medicine industrial hub [3][4] - New policy measures have been introduced to address challenges in the nuclear medicine sector, focusing on regulatory efficiency, innovation, market demand, and a supportive environment [3][5][6] Regulatory Efficiency - Six measures have been proposed to enhance regulatory efficiency, including the establishment of a more scientific and effective regulatory system [3] - The government aims to streamline regulations for new treatment technologies, such as Flash radiation therapy, and support the development of relevant guidelines [3][4] Innovation Empowerment - Four measures are focused on fostering innovation in the nuclear medicine sector, including support for research on new drug targets and the establishment of integrated platforms for industry-academia-research collaboration [4] - The government encourages joint innovation among industry players to enhance the overall development of the nuclear medicine field [4] Expanding Market Demand - Seven measures aim to stimulate end-user demand, which is expected to drive growth across the entire nuclear medicine supply chain [5][6] - Initiatives include promoting the application of domestic nuclear medical equipment in hospitals and encouraging the development of commercial insurance products related to nuclear medicine [6] Supportive Environment - Seven measures are designed to create a favorable environment for the nuclear medicine industry, including the establishment of a consultation mechanism for the industry chain and the promotion of government investment funds [6][7] - The government plans to address financing challenges faced by nuclear medicine enterprises by leveraging policy financial tools and encouraging public-private partnerships [7]

Core Viewpoint - The company, Foci Pharmaceutical, is strategically investing in the radioactive isotope drug sector to enhance its core competitiveness by signing an investment agreement with Kejin Taiji New Technology Co., Ltd. [1] Investment Details - On October 10, the company announced a cash investment of 20 million yuan in Kejin Taiji, acquiring a 4.911% stake in the company post-investment [1]. Collaboration and Future Plans - Kejin Taiji is designated as the industrialization entity for medical isotopes by the Institute of Modern Physics of the Chinese Academy of Sciences, indicating a strong collaboration for future projects [1]. - The primary business of Kejin Taiji will involve cooperation with the Institute of Modern Physics and Gansu Isotope Laboratory to engage in the production, sales, operations, and collaborative research and development of medical isotopes [1].